Blood substitutes comprising hemoglobin and methods of making

Inventors

Light, William Richard • Tucker, Joseph

Assignees

Virtech Bio Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12582703-B2

Patent

Publication Date

2026-03-24

Expiration Date


Abstract

Methods for making hemoglobin based blood substitute preparations and hemoglobin based blood substitute preparations. The methods involve preparing a low purity erythrocyte protein fraction comprising hemoglobin protein and endogenous non-hemoglobin protein complement, and chemically modifying the proteins in the protein fraction to form a cross-linked hemoglobin containing blood substitute preparation. The low purity erythrocyte protein preparation can contain from at least about 0.2% (mole/mole) up to about 20% (mole/mole) endogenous non-hemoglobin protein complement. At least about 90% (mole/mole) of the hemoglobin proteins can be cross-linked, so that the average molecular mass of cross-linked proteins comprising hemoglobin protein molecules in the preparation is at least about 300 kDa. The preparations can be used to prepare finished blood substitute formulations for in-vivo and ex-vivo use.

Core Innovation

A blood substitute preparation is prepared using hemoglobin from isolated erythrocytes. The method isolates a low purity erythrocyte protein fraction that includes hemoglobin protein molecules together with an endogenous non-hemoglobin protein complement, and the endogenous non-hemoglobin protein complement comprises carbonic anhydrase.

The low purity erythrocyte protein fraction is contacted with a reactant capable of chemically modifying the proteins in the protein fraction. The reactant mediates the formation of cross-linked proteins comprising intermolecular cross-linkages between the hemoglobin protein molecules and intermolecular cross-linkages between the hemoglobin protein molecules and the endogenous non-hemoglobin protein complement.

The described approach emphasizes avoiding highly purified hemoglobin and avoiding borohydride (BH4−) in the processing. The resulting products are characterized as having at least about 90% cross-linked hemoglobin and an average cross-linked protein molecular mass of at least about 300 kDa, with optional characteristics described for about 1000 kDa.

Claims Coverage

The document provides coverage for at least one independent method claim focused on preparing a hemoglobin-based blood substitute via isolation of a low-purity erythrocyte protein fraction that includes an endogenous non-hemoglobin protein complement, including carbonic anhydrase, followed by chemically mediating formation of cross-linked proteins with specified intermolecular cross-linking relationships.

Low-purity erythrocyte protein fraction with endogenous non-hemoglobin complement

Isolating a low purity erythrocyte protein fraction comprising hemoglobin protein molecules and an endogenous non-hemoglobin protein complement from erythrocytes, where the low purity erythrocyte protein fraction comprises from at least about 0.2% (mole/mole) up to about 20% (mole/mole) of the endogenous non-hemoglobin protein complement, the endogenous non-hemoglobin protein complement comprising carbonic anhydrase.

Chemically mediating intermolecular cross-linkages in the protein fraction

Contacting the low purity erythrocyte protein fraction with a reactant capable of chemically modifying the proteins in the protein fraction, the reactant thereby mediating the formation of cross-linked proteins comprising intermolecular cross-linkages between the hemoglobin protein molecules, and intermolecular cross-linkages between the hemoglobin protein molecules and the endogenous non-hemoglobin protein complement, to thereby form a blood substitute preparation.

The independent claim coverage centers on preparing a hemoglobin-based blood substitute by isolating a low-purity erythrocyte protein fraction that retains endogenous non-hemoglobin protein complement including carbonic anhydrase at a defined mole/mole fraction, and chemically mediating formation of cross-linked proteins with intermolecular cross-linkages both among hemoglobin protein molecules and between hemoglobin and the endogenous non-hemoglobin complement.

Stated Advantages

Produces blood substitute preparations having at least about 90% cross-linked hemoglobin.

Produces cross-linked proteins having an average cross-linked protein molecular mass of at least about 300 kDa.

Avoids highly purified hemoglobin.

Avoids borohydride (BH4−).

Documented Applications

In-vivo administration of the blood substitute preparation.

Ex-vivo organ perfusion and preservation using the blood substitute preparation.

Example evaluations are described using rats and swine liver.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.